Cardioprotective effects of fullerenol C60(Oh)24 on a single dose doxorubicin-induced cardiotoxicity in rats with malignant neoplasm
Cardioprotective effects of fullerenol C60(Oh)24 on a single dose doxorubicin-induced cardiotoxicity in rats with malignant neoplasm
复制标题
DOI：
10.1177/153303460800700102
复制
发表时间：
2008-02-01
影响因子：
2.8
通讯作者：
Strukej, Borut
中科院分区：
文献类型：
--
作者：
Injac, Rade;Perse, Martina;Strukej, Borut
由于其心脏毒性，蒽环类抗生素阿霉素的治疗作用受到限制。我们的目的是研究富勒烯醇C-60(OH)(24)预防单次大剂量阿霉素引起的恶性肿瘤大鼠心脏毒性的效果。本实验是在成年雌性SD大鼠化学诱发乳腺癌模型上进行的。应用阿霉素和/或富勒烯醇后2d处死动物，测定血清CK、LDH、α-HBDH活性及心脏组织中MDA、GSH、GSSG、GSH-Px、SOD、CAT、GR、TAS的含量。血清酶活性测定结果表明，单次给药8 mg/kg组对小鼠的损伤有统计学意义。腹腔注射后LDH、CK酶有显著变化(P<0.05)。阿霉素/富勒醇和富勒醇的给药。将各剂量组与未经处理的对照组进行比较，得出结论：在α-HBDH/LDH比值较低的情况下，导致肝实质损伤更严重。结果表明，阿霉素可引起大鼠心脏组织氧化损伤，而富勒烯醇致大鼠心脏组织中MDA、GSH、GSSG、GSH-Px、SOD、CAT、GR和TAS水平明显升高(p<；0.05)。因此，富勒烯醇可能是阿霉素治疗患者的一种潜在的心脏保护剂。
The therapeutic utility of the anthracycline antibiotic doxorubicin is limited due to its cardiotoxicity. Our aim was to investigate the efficacy of fullerenol C-60(OH)(24) in preventing single, high-dose doxorubicin-induced cardiotoxicity in rats with malignant neoplasm. Experiment was performed on adult female Sprague Dawley rats with chemically induced mammary carcinomas. The animals were sacrificed two days after the application of doxorubicin and/or fullerenol, and the serum activities of CK, LDH and alpha-HBDH, as well as the levels of MDA, GSH, GSSG, GSH-Px, SOD, CAT, GR, and TAS in the heart, were determined. The results obtained from the enzymatic activity in the serum show that the administration of a single dose of 8 mg/kg in all treated groups induces statistically significant damage. There are significant changes in the enzymes of LDH and CK (p < 0.05), after an i.p. administration of doxorubicin/fullerenol and fullerenol. Comparing all groups with untreated control group, point to the conclusion that in the case of a lower alpha-HBDH/LDH ratio, results in more serious the liver parenchymal damage. The results revealed that doxorubicin induced oxidative damage and that the fullerenol antioxidative influence caused significant changes in MDA, GSH, GSSG, GSH-Px, SOD, CAT, GR, and TAS level in the heart (p < 0.05). Therefore, it is suggested that fullerenol might be a potential cardioprotector in doxorubicin-treated individuals.